Osimertinib is also being studied in the Phase III NeoADAURA trial (NCT04351555), which is assessing neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone prior to surgery, in patients with resectable stage II-IIIB N2 EGFR mutation-positive NSCLC (14). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.